BARKLEY 3PS REVIEW EXAM
BANK: COMPLETE COLLECTION
OF LATEST ACTUAL EXAM
LATEST MOCK PRACTICE SET
250 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
BARKLEY 3PS REVIEW EXAM BANK: COMPLETE COLLECTION OF LATEST ACTUAL EXAM QUESTIONS
WITH CORRECT DETAILED ANSWERS AND RATIONALES, ALREADY GRADED A+. It contains 250 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 250 Questions
Foundations - Application - Barkley 3ps Review BANK Complete Collection OF Actual WITH Correct
Detailed AND Rationales Already A Comprehensive Pharmacology Pathophysiology AND Clinical
Therapeutics Graduate / Advanced Undergraduate YEAR 4
All answers with rationales
,Table of Contents
Section A - Management OF CARE Section B - Safety AND Infection
Questions 1 to 63 Control
Questions 64 to 126
Section C - Health Promotion AND Section D - Psychosocial Integrity
Maintenance Questions 190 to 250
Questions 127 to 189
,Section A - Management OF CARE
Q1.
A drug exhibits a volume of distribution of 0.5 L/kg and a clearance of 0.05 L/hr/kg. What
is its elimination half-life?
A. 6.93 hours B. 10.0 hours
C. 13.9 hours D. 20.0 hours
Correct: A - 6.93 hours
Rationale:Half-life = (0.693 * Vd) / Cl = (0.693 * 0.5) / 0.05 = 0..05 = 6.93 hours.
Option B results from using 1.0 instead of 0.693; C uses Vd incorrectly; D uses Cl incorrectly.
Q2.
A patient on warfarin develops an INR of 5.2 without bleeding. Which reversal agent is
most appropriate?
A. Protamine sulfate B. Vitamin K (oral)
C. Phytonadione (IV) plus fresh frozen D. Idarucizumab
plasma
Correct: B - Vitamin K (oral)
Rationale:For elevated INR without bleeding, oral vitamin K is first-line. IV vitamin K or FFP is
reserved for serious bleeding. Protamine reverses heparin; idarucizumab reverses
dabigatran.
Q3.
Which of the following best describes the mechanism of action of metformin?
A. Increases insulin secretion from B. Activates AMPK, reducing hepatic
pancreatic beta cells gluconeogenesis and increasing peripheral
insulin sensitivity
C. Inhibits alpha-glucosidase in the small D. Binds to PPAR-gamma receptors to
intestine enhance insulin sensitivity
Correct: B - Activates AMPK, reducing hepatic gluconeogenesis and increasing peripheral
insulin sensitivity
Rationale:Metformin primarily activates AMPK, decreasing hepatic glucose output and
improving insulin sensitivity. Option A describes sulfonylureas; C describes acarbose; D
describes thiazolidinediones.
Page 3
, Section A - Management OF CARE
Q4.
A patient with asthma uses a short-acting beta-agonist (SABA) more than twice weekly for
symptom relief. According to current GINA guidelines, what is the recommended step-up
therapy?
A. Add a leukotriene receptor antagonist B. Add a low-dose inhaled corticosteroid
(ICS) as a controller
C. Switch to a long-acting beta-agonist D. Increase SABA frequency as needed
(LABA) alone
Correct: B - Add a low-dose inhaled corticosteroid (ICS) as a controller
Rationale:GINA 2023 recommends low-dose ICS for patients using SABA >2 times/week.
LABA alone is not recommended; leukotriene receptor antagonists are alternative but not
first-line step-up.
Q5.
Which drug interaction is most likely to cause a dangerous increase in methotrexate
toxicity?
A. Coadministration with folic acid B. Coadministration with
trimethoprim-sulfamethoxazole
C. Coadministration with omeprazole D. Coadministration with acetaminophen
Correct: B - Coadministration with trimethoprim-sulfamethoxazole
Rationale:Trimethoprim-sulfamethoxazole inhibits dihydrofolate reductase, additive to
methotrexate's effect, increasing risk of severe myelosuppression. Folic acid reduces toxicity;
omeprazole and acetaminophen have minor interactions.
Q6.
A patient on lithium develops polyuria and polydipsia. Urinalysis reveals low specific
gravity. Which mechanism best explains this adverse effect?
A. Nephrogenic diabetes insipidus due to B. Osmotic diuresis from lithium-induced
impaired renal concentrating ability glucosuria
C. Central diabetes insipidus from D. SIADH-like effect with water retention
decreased ADH production
Correct: A - Nephrogenic diabetes insipidus due to impaired renal concentrating ability
Rationale:Lithium causes nephrogenic diabetes insipidus by interfering with ADH-mediated
water reabsorption in collecting ducts. It does not cause glucosuria or central DI; SIADH
would cause hyponatremia and concentrated urine.
Page 4
BANK: COMPLETE COLLECTION
OF LATEST ACTUAL EXAM
LATEST MOCK PRACTICE SET
250 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
BARKLEY 3PS REVIEW EXAM BANK: COMPLETE COLLECTION OF LATEST ACTUAL EXAM QUESTIONS
WITH CORRECT DETAILED ANSWERS AND RATIONALES, ALREADY GRADED A+. It contains 250 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 250 Questions
Foundations - Application - Barkley 3ps Review BANK Complete Collection OF Actual WITH Correct
Detailed AND Rationales Already A Comprehensive Pharmacology Pathophysiology AND Clinical
Therapeutics Graduate / Advanced Undergraduate YEAR 4
All answers with rationales
,Table of Contents
Section A - Management OF CARE Section B - Safety AND Infection
Questions 1 to 63 Control
Questions 64 to 126
Section C - Health Promotion AND Section D - Psychosocial Integrity
Maintenance Questions 190 to 250
Questions 127 to 189
,Section A - Management OF CARE
Q1.
A drug exhibits a volume of distribution of 0.5 L/kg and a clearance of 0.05 L/hr/kg. What
is its elimination half-life?
A. 6.93 hours B. 10.0 hours
C. 13.9 hours D. 20.0 hours
Correct: A - 6.93 hours
Rationale:Half-life = (0.693 * Vd) / Cl = (0.693 * 0.5) / 0.05 = 0..05 = 6.93 hours.
Option B results from using 1.0 instead of 0.693; C uses Vd incorrectly; D uses Cl incorrectly.
Q2.
A patient on warfarin develops an INR of 5.2 without bleeding. Which reversal agent is
most appropriate?
A. Protamine sulfate B. Vitamin K (oral)
C. Phytonadione (IV) plus fresh frozen D. Idarucizumab
plasma
Correct: B - Vitamin K (oral)
Rationale:For elevated INR without bleeding, oral vitamin K is first-line. IV vitamin K or FFP is
reserved for serious bleeding. Protamine reverses heparin; idarucizumab reverses
dabigatran.
Q3.
Which of the following best describes the mechanism of action of metformin?
A. Increases insulin secretion from B. Activates AMPK, reducing hepatic
pancreatic beta cells gluconeogenesis and increasing peripheral
insulin sensitivity
C. Inhibits alpha-glucosidase in the small D. Binds to PPAR-gamma receptors to
intestine enhance insulin sensitivity
Correct: B - Activates AMPK, reducing hepatic gluconeogenesis and increasing peripheral
insulin sensitivity
Rationale:Metformin primarily activates AMPK, decreasing hepatic glucose output and
improving insulin sensitivity. Option A describes sulfonylureas; C describes acarbose; D
describes thiazolidinediones.
Page 3
, Section A - Management OF CARE
Q4.
A patient with asthma uses a short-acting beta-agonist (SABA) more than twice weekly for
symptom relief. According to current GINA guidelines, what is the recommended step-up
therapy?
A. Add a leukotriene receptor antagonist B. Add a low-dose inhaled corticosteroid
(ICS) as a controller
C. Switch to a long-acting beta-agonist D. Increase SABA frequency as needed
(LABA) alone
Correct: B - Add a low-dose inhaled corticosteroid (ICS) as a controller
Rationale:GINA 2023 recommends low-dose ICS for patients using SABA >2 times/week.
LABA alone is not recommended; leukotriene receptor antagonists are alternative but not
first-line step-up.
Q5.
Which drug interaction is most likely to cause a dangerous increase in methotrexate
toxicity?
A. Coadministration with folic acid B. Coadministration with
trimethoprim-sulfamethoxazole
C. Coadministration with omeprazole D. Coadministration with acetaminophen
Correct: B - Coadministration with trimethoprim-sulfamethoxazole
Rationale:Trimethoprim-sulfamethoxazole inhibits dihydrofolate reductase, additive to
methotrexate's effect, increasing risk of severe myelosuppression. Folic acid reduces toxicity;
omeprazole and acetaminophen have minor interactions.
Q6.
A patient on lithium develops polyuria and polydipsia. Urinalysis reveals low specific
gravity. Which mechanism best explains this adverse effect?
A. Nephrogenic diabetes insipidus due to B. Osmotic diuresis from lithium-induced
impaired renal concentrating ability glucosuria
C. Central diabetes insipidus from D. SIADH-like effect with water retention
decreased ADH production
Correct: A - Nephrogenic diabetes insipidus due to impaired renal concentrating ability
Rationale:Lithium causes nephrogenic diabetes insipidus by interfering with ADH-mediated
water reabsorption in collecting ducts. It does not cause glucosuria or central DI; SIADH
would cause hyponatremia and concentrated urine.
Page 4
